High-dose dexamethasone therapy in chronic idiopathic thrombocytopenic purpura

Ann Hematol. 1996 Oct;73(4):175-7. doi: 10.1007/s002770050223.

Abstract

A high-dose pulse of dexamethasone has been described as a current option for the treatment of refractory idiopathic thrombocytopenic purpura (ITP), but the results are controversial. Here we describe the use of a high does of dexamethasone (40 mg per day for 4 days every month) in 18 patients with chronic ITP. The median age of the patients was 42.5 years (range, 16-77 years); 13 were female and five male. The duration of the disease ranged from 5 to 480 months, and splenectomy was carried out in six of the 18 patients. the overall results obtained revealed a satisfactory response (platelet counts higher than 50 x 10(9)/l) in eight of the 18 patients. However, a long-term remission was achieved in only three of the eight patients with a follow up of 7-16 months. We were not able to identify any clinical or laboratory prognostic parameters or previous treatment which would allow one to predict a successful outcome of this treatment. These results suggest that a high dose of dexamethasone may provide an alternative, be it a poor one, for the treatment of refractory IPT, in which the use of a low-cost drug with limited side effects is an important consideration.

MeSH terms

  • Adolescent
  • Adult
  • Dexamethasone / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Glucocorticoids / administration & dosage
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Splenectomy

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Dexamethasone